Quantum Cyber N.V. Expands ATM Program to $100M, CFO Transitions to Consulting Role
QUCY is trading near its 52-week low of $0.34 (6.8% above the low) on light trading volume (0.3× avg).
Summary
Quantum Cyber N.V. significantly increased its At-The-Market (ATM) equity offering program to $100 million, a substantial potential dilution relative to its market cap, while its CFO transitioned to a consulting agreement with a $20,000 monthly retainer.
Key Events · Financing and Capital Events · QUCY
-
ATM Program Expanded to $100 Million
The company amended its Equity Distribution Agreement with Maxim Group LLC, increasing the aggregate offering amount of ordinary shares that can be sold from $10 million to $100 million. This is an update to an existing program established on October 3, 2025, and represents a potential dilution significantly exceeding the company's current market capitalization.
-
CFO Transitions to Consulting Agreement
William Caragol, the Chief Financial Officer, entered into a consulting agreement effective April 22, 2026, to continue providing financial and accounting services. He will receive a monthly retainer of $20,000, with potential for stock or option grants. This transition marks a change in executive structure and introduces a significant ongoing operational cost relative to the company's size.
Analysis · QUCY · Life Sciences
Quantum Cyber N.V. has significantly expanded its At-The-Market (ATM) equity program to $100 million, a move that represents an extremely high potential for dilution given the company's current market capitalization. This follows a recent highly dilutive $6 million private placement and the company's prior disclosure of substantial doubt about its ability to continue as a going concern. The massive increase in the ATM program signals an urgent need for capital, likely at terms highly unfavorable to existing shareholders. Additionally, the company's CFO has transitioned to a consulting agreement with a monthly retainer of $20,000, which is a notable expense for a company of this size and financial standing, raising questions about executive stability and operational costs.
At the time of this filing, QUCY was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.34 to $2.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.